KO Cancer Act
HR 3873 (KO Cancer Act) directs the National Cancer Institute (NCI) to receive 25% more annual funding for cancer research in fiscal years 2026-2030 compared to 2022 levels, with these funds in addition to existing appropriations. It also requires the Department of Health and Human Services to study the causes of cancer drug shortages - including economic factors, supply chain issues, and regulatory delays - and submit a report with recommendations to Congress within one year of enactment. The bill directly affects the NCI, cancer researchers, and patients by increasing research funding and addressing drug access barriers. Its key provisions are a specific funding increase for NCI research and a mandated study on cancer drug shortages, aiming to improve treatment availability through evidence-based solutions.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jun 2025
Committee Review
Floor Vote
President
Introduced Jun 10, 2025
Last action Jun 10, 2025
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Jun 10, 2025
Committee
Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jun 10, 2025
Introduced
Introduced in House
lower
1 primary · 6 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 3873
Scope: US
Hi! I can help you understand HR 3873. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline